Feinstein Institute for — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$109,984	13
2024	Research	$14,039	7
2023	Research	$53,771	6
2022	Research	$17,280	3
2021	Research	$30,318	1

Breakdown

Who paid Research payments · program years 2021–2025

AbbVie, Inc. $158,311 17 payments
SI-BONE, Inc. $35,764 11 payments
Merck Sharp & Dohme Corporation $30,318 1 payment
Pfizer Inc. $1,000 1 payment

Studies the money was for Research payments · program years 2021–2025

Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease $53,986 3 payments
Paula $35,764 11 payments
An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate Slow Early Response to Frontline Chemotherapy KEYNOTE 667 $30,318 1 payment
Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis $29,898 4 payments
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease $29,580 1 payment
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitisx2FBladder Pain Syndrome (ICx2FBPS) $16,280 2 payments
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis;Bladder Pain Syndrome $14,164 2 payments
A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED) $8,446 1 payment
A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED) $3,570 1 payment
M21-446 - Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis $2,040 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.